Subject category:
Strategy and General Management
Published by:
Amity Research Centers
Length: 10 pages
Data source: Published sources
Share a link:
https://casecent.re/p/191551
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
In 2023, Japanese pharma giant Ono Pharmaceutical Co, Ltd (Ono) signed a drug discovery pact with another Japanese concern PeptiDream Inc, (PeptiDream). Earlier, the two companies had built their partnership after the non-exclusive licensing of the automated Peptide Discovery Platform System (PDPS) technology of PeptiDream in March 2021. The aim of the new collaboration was to discover as well as develop innovative macrocyclic constrained peptide drugs against several targets of Ono's interest. While both the companies were upbeat about the collaboration, challenges underlying drug discovery and development were known facts, so were the collaborations underlying such ventures. In such a scenario, would the collaboration succeed thwarting all the underlying challenges?
Teaching and learning
This item is suitable for undergraduate, postgraduate and executive education courses.Time period
The events covered by this case took place in 2023.Geographical setting
Region:
World/global
Featured companies
Ono Pharmaceutical Co, Ltd
Employees:
1001-5000
Type:
Public company
PeptiDream Inc
Employees:
51-200
Type:
Public company
Featured protagonists
- Toichi Takino (male), Executive Director, Discovery and Research, Ono
- Keiichi Masuya (male), Chief Operating Officer, PetiDream
Subject category:
Strategy and General Management
Published by:
Amity Research Centers
Length: 6 pages
Data source: Published sources
About
Abstract
In 2023, Japanese pharma giant Ono Pharmaceutical Co, Ltd (Ono) signed a drug discovery pact with another Japanese concern PeptiDream Inc, (PeptiDream). Earlier, the two companies had built their partnership after the non-exclusive licensing of the automated Peptide Discovery Platform System (PDPS) technology of PeptiDream in March 2021. The aim of the new collaboration was to discover as well as develop innovative macrocyclic constrained peptide drugs against several targets of Ono's interest. While both the companies were upbeat about the collaboration, challenges underlying drug discovery and development were known facts, so were the collaborations underlying such ventures. In such a scenario, would the collaboration succeed thwarting all the underlying challenges?
Teaching and learning
This item is suitable for undergraduate, postgraduate and executive education courses.Settings
Time period
The events covered by this case took place in 2023.Geographical setting
Region:
World/global
Featured companies
Ono Pharmaceutical Co, Ltd
Employees:
1001-5000
Type:
Public company
PeptiDream Inc
Employees:
51-200
Type:
Public company
Featured protagonists
- Toichi Takino (male), Executive Director, Discovery and Research, Ono
- Keiichi Masuya (male), Chief Operating Officer, PetiDream
Related
Subject category:
Strategy and General Management
Published by:
Amity Research Centers
Length: 6 pages
Data source: Published sources